The Regents of the University of California, San Francisco (UCSF) has been awarded a $676,567 project grant under the National Cancer Institute's (NCI) Cancer Treatment Research program (CFDA 93.395). The grant, with a performance period from December 16, 2024 to November 30, 2029, will fund systematic preclinical testing of a transforming growth factor beta (TGFβ)-targeted theranostic approach for cancer treatment.
The project aims to develop and evaluate a TGFβ-targeted radiopharmaceutical therapy (RPT) by radiolabeling a clinically validated TGFβ neutralizing antibody with imaging (89Zr) and therapeutic (177Lu) isotopes. The researchers will assess the pharmacokinetics, dosimetry, and relative biological effectiveness of the TGFβ-RPT across five mouse cancer models with varying levels of TGFβ activity, tissue origin, and radiosensitivity. The goal is to delineate the interactions between delivered radiation dose and underlying biological mechanisms that determine the efficacy of this tumor-agnostic theranostic approach.
Generated 3/4/25, 8:16 AM